When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
RLMD - Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Relmada Therapeutics Inc.
2024-03-21 18:57:54 ET
Summary
RLMD plans to report results from the phase 3 Reliance II study of REL-1017, as an adjunctive treatment for major depressive disorder, in H2 2024.
The current timeline for completion of enrolment in Reliance II may suggest a slight slippage, but my position on the potential for a run up is unchanged.
RLMD notes it has cash to complete its current studies Reliance II and Relight, as well as a phase 1 study of modified release psilocybin.